Inflammatory Gastroenterology is a debilitating condition resulting from inflammation in the intestinal tract, affecting approximately 1 in every 250 people in the UK (currently more than 300,000 cases). Inflammatory Gastroenterology occurs as two distinct conditions, ulcerative colitis and Crohn’s disease, as well as primary sclerosing cholangitis associated with Inflammatory Gastroenterology. This theme, which is led by Professor Subrata Ghosh, focuses on addressing several unmet needs:
- To reduce the huge cost associated with targeted therapy against Inflammatory Gastroenterology.
- To stratify therapy for patients with Inflammatory Gastroenterology, in a world where multiple classes of therapy now exist.
- To help overcome the real lack of treatment for preventing progression of PSC, which is an important extra-intestinal manifestation of Inflammatory Gastroenterology.
- To precisely identify Inflammatory Gastroenterology patients in whom targeted therapies may be discontinued.
- While microbiome manipulation is attracting considerable attention, there is a significant necessity to identify the right patient and donor for applying Fecal Microbiota Transplantation for Inflammatory Bowel Disease.
- Finally, there is an important need to prevent/treat colitis as a treatment-limiting complication of new anti-cancer drugs.
Tackling these unmet needs are core to the complementary aims of the Inflammatory Gastroenterology theme and will allow the NIHR Biomedical Research Centre to deliver internationally competitive, NIHR funded, Industry relevant, and for patient benefit research. The aims for the Inflammatory Gastroenterology theme are as follows:
- Precision medicine in the diagnosis, prognosis and treatment of Inflammatory Gastroenterology
- Therapy and risk prediction in PSC-IBD (Inflammatory Bowel Disease) and;
- Microbiome modulation as a treatment of inflammatory gastrointestinal diseases